Z Squared (ZSQR) Q3 2024 earnings summary

Executive summary

• Focus remains on product development, capital raising, and infrastructure building, with no significant revenue expected for at least two years as drug development continues toward commercialization through partnerships or other means.

• Operating expenses decreased significantly year-over-year, primarily due to lower professional services expenses related to equity transactions.

• The company completed multiple closings of a Series A Preferred Stock offering, raising $5.8 million and forming two new subsidiaries, SNAP Biosciences and GEAR Therapeutics.

Financial highlights

• Net loss for the nine months ended September 30, 2024 was $7,865,647, compared to $17,510,948 for the same period in 2023.

• Operating expenses for the nine months ended September 30, 2024 were $7,892,274, down from $18,125,156 year-over-year.

• Cash and cash equivalents decreased to $1,137,453 as of September 30, 2024, from $1,469,134 at December 31, 2023.

• Weighted average shares outstanding increased to 39,806,505 for the quarter, reflecting equity issuances.

Outlook and guidance

• Management does not expect significant revenue for at least the next two years, as focus remains on advancing drug development and seeking commercialization partnerships.

• The ability to raise capital through equity transactions is expected to support liquidity and execution of operating strategy.